ACT on HCV - A Practical Introduction to Treating HCV

ACT on HCV - A Practical Introduction to Treating HCV

Module 1: HCV Overview

CME/CE(NURSE) ACTIVITY


HoChong Gilles, RN, MS, FNP-C
HoChong Gilles, RN, MS, FNP-C
Disclosure(s): Nothing to disclose 
49 slide(s)– English – 2012-10-01
-Identify the Natural history of hepatitis C virus (HCV) infection
-Explain HCV screening and diagnosis
-List the Goals of HCV treatment
-Name the Guidelines in genotype 1 (GT1) infection with currently approved HCV treatments (including direct acting anti-viral agents)
Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. "The prevalence of hepatitis C virus infection in the United States, 1988 through 1994." N Engl J Med. 1999 Aug 19;341(8):556-62.
[See Reference]

Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. “The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.” Ann Intern Med. 2006 May 16;144(10):705-14.
[See Reference]

Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. “The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.” N Engl J Med. 1999 Aug 19;341(8):556-62.
[See Reference]

Centers for Disease Control and Prevention. “Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease.” MMWR Recomm Rep. 1998 Oct 16;47(RR-19):1-39.
[See Reference]

Wong JB, McQuillan GM, McHutchison JG, Poynard T. “Estimating future hepatitis C morbidity, mortality, and costs in the United States.” Am J Public Health. 2000 Oct;90(10):1562-9.
[See Reference]

Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. “The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007.” Ann Intern Med. 2012 Feb 21;156(4):271-8.
[See Reference]

Alter MJ. “Epidemiology of hepatitis C.” Hepatology. 1997 Sep;26(3 Suppl 1):62S-65S.
[See Reference]

Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. “Diagnosis, management, and treatment of hepatitis C: an update.” Hepatology. 2009 Apr;49(4):1335-74.
[See Reference]

National Institutes of Health. “National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.” Hepatology. 2002 Nov;36(5 Suppl 1):S3-20.
[See Reference]

Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. “Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.” Gastroenterology. 2010 Feb;138(2):513-21, 521.e1-6. Epub 2009 Oct 25.
[See Reference]

Missiha SB, Ostrowski M, Heathcote EJ. “Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors.” Gastroenterology. 2008 May;134(6):1699-714.
[See Reference]

Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, Opolon P. “Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C.” Arthritis Rheum. 1999 Oct;42(10):2204-12.
[See Reference]

Shiffman ML, Stewart CA, Hofmann CM, Contos MJ, Luketic VA, Sterling RK, Sanyal AJ. “Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy.” J Infect Dis. 2000 Dec;182(6):1595-601. Epub 2000 Oct 23.
[See Reference]

Pawlotsky JM. “Use and interpretation of virological tests for hepatitis C.” Hepatology. 2002 Nov;36(5 Suppl 1):S65-73.
[See Reference]

Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. “Diagnosis, management, and treatment of hepatitis C: an update.” Hepatology. 2009 Apr;49(4):1335-74.
[See Reference]

Zein NN. “Clinical significance of hepatitis C virus genotypes.” Clin Microbiol Rev. 2000 Apr;13(2):223-35.
[See Reference]

Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. “Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.” Nature. 2009 Sep 17;461(7262):399-401. Epub 2009 Aug 16.
[See Reference]

Brunt EM. “Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond.” Hepatology. 2000 Jan;31(1):241-6.
[See Reference]

Colletta C, Smirne C, Fabris C, Toniutto P, Rapetti R, Minisini R, Pirisi M. “Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases.” Hepatology. 2005 Oct;42(4):838-45.
[See Reference]

Halfon P, Bourliere M, Deydier R, Botta-Fridlund D, Renou C, Tran A, Portal I, Allemand I, Bertrand JJ, Rosenthal-Allieri A, Rotily M, Sattonet C, Benderitter T, Saint Paul MC, Bonnot HP, Penaranda G, Degott C, Masseyeff MF, Ouzan D. “Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study.” Am J Gastroenterol. 2006 Mar;101(3):547-55.
[See Reference]

Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, Degott C, Erlinger S. “Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.” Ann Intern Med. 1997 Nov 15;127(10):875-81.
[See Reference]

Pockros PJ, Hamzeh FM, Martin P, Lentz E, Zhou X, Govindarajan S, Lok AS. “Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments.” Hepatology. 2010 Oct;52(4):1193-200.
[See Reference]
Media: Internet
Release date: November 10, 2012
Updated Date: November 10, 2013
Expiration date: November 10, 2014
The slide set was reviewed by the author and no updates were needed.
Time to complete the activity: 45 minutes

CME
Accreditation Statement
The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
AASLD designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE(Nurse)
The Institute for Advancement of Human Behavior is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This course is co-provided by IAHB and AASLD. Maximum of .75 contact hours.

Target Audience
This curriculum was developed for medical professionals with little or no experience providing care to patients with HCV.

Components
-Online interactive, narrated module 30 to 40 minutes in length
-Pre-and post-test questions
-Evaluation
EXPAND
COLLAPSE

Module 2: HCV Genotyping and Predictors of Response

CME/CE(NURSE) ACTIVITY


Michael Surdy
Michael Surdy
Disclosure(s): I have no conflicts of interest regarding any of the products mentioned during this presentation. 
40 slide(s)– English – 2012-10-01
-Name the role of hepatitis C genotyping in the treatment of chronic hepatitis C
-Identify both patient and viral factors that affect response to hepatitis C antiviral therapy
-Explain how to Predict response rates in patients who did not achieve a sustained virological response (SVR) to prior therapy
-Describe a patient's chances of achieving SVR
Kau A, Vermehren J, Sarrazin C. "Treatment predictors of a sustained virologic response in hepatitis B and C." J Hepatol. 2008 Oct;49(4):634-51.
[See Reference]

Thompson AJ et al. "Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus." Gastroenterology. 2010 Jul;139(1):120-9.
[See Reference]

Hugo R. Rosen."Chronic Hepatitis C Infection" N Engl J Med 2011; 364:2429-2438.
[See Reference]

Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases."Diagnosis, management, and treatment of hepatitis C: an update." Hepatology. 2009 Apr;49(4):1335-74.
[See Reference]

McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK."Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group." N Engl J Med. 1998 Nov 19;339(21):1485-92.
[See Reference]

McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team."Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection." N Engl J Med. 2009 Aug 6;361(6):580-93.
[See Reference]

Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S. “Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis.” Aliment Pharmacol Ther. 2008 Aug 15;28(4):397-404.
[See Reference]

Duarte-Rojo A, Heathcote EJ, Feld JJ."'Easy to treat' genotypes were not created equal: can rapid virological response (RVR) level the playing field?" J Hepatol. 2011 Aug;55(2):466-73.
[See Reference]

Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team."Telaprevir for previously untreated chronic hepatitis C virus infection." N Engl J Med. 2011 Jun 23;364(25):2405-16.
[See Reference]

Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators. "Boceprevir for untreated chronic HCV genotype 1 infection." N Engl J Med. 2011 Mar 31;364(13):1195-206.
[See Reference]

McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ; PROVE1 Study Team."Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection." N Engl J Med. 2009 Apr 30;360(18):1827-38.
[See Reference]

Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, Monto A; Department of Veterans Affairs Hepatitis C Resource Center Program; National Hepatitis C Program Office."Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office." Am J Gastroenterol. 2012 May;107(5):669-89.
[See Reference]

Zeuzem S, et al."Telaprevir for retreatment of HCV infection." N Engl J Med. 2011 Jun 23;364(25):2417-28.
[See Reference]

Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R; HCV RESPOND-2 Investigators. "Boceprevir for previously treated chronic HCV genotype 1 infection." N Engl J Med. 2011 Mar 31;364(13):1207-17.
[See Reference]

Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB."Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance." Nature. 2009 Sep 17;461(7262):399-401.
[See Reference]

Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M."Genetic variation in IL28B and spontaneous clearance of hepatitis C virus." Nature. 2009 Oct 8;461(7265):798-801.
[See Reference]

Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M."Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C." Nat Genet. 2009 Oct;41(10):1105-9.
[See Reference]

Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ."Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin." Hepatology. 2003 Jun;37(6):1343-50.
[See Reference]

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK."Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial." Lancet. 2001 Sep 22;358(9286):958-65.
[See Reference]

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J."Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection." N Engl J Med. 2002 Sep 26;347(13):975-82.
[See Reference]

Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J."Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C." Hepatology. 2003 Jul;38(1):75-85.
[See Reference]

McCullough AJ. “Obesity and its nurturing effect on hepatitis C.” Hepatology. 2003 Sep;38(3):557-9.
[See Reference]

Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M."Meta-analysis: insulin resistance and sustained virological response in hepatitis C." Aliment Pharmacol Ther. 2011 Aug;34(3):297-305.
[See Reference]

Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ."Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis." Clin Infect Dis. 2001 Aug 15;33(4):562-9.
[See Reference]

Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C; AIDS Clinical Trials Group A5071 Study Team."Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons." N Engl J Med. 2004 Jul 29;351(5):451-9.
[See Reference]

Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT; APRICOT Study Group."Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients." N Engl J Med. 2004 Jul 29;351(5):438-50.
[See Reference]

Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, Perronne C; ANRS HCO2 RIBAVIC Study Team. "Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial." JAMA. 2004 Dec 15;292(23):2839-48.
[See Reference]
Media: Internet
Release date: November 10, 2012
Updated Date: November 10, 2013
Expiration date: November 10, 2014
The slide set was reviewed by the author and no updates were needed.
Time to complete the activity: 45 minutes

CME
Accreditation Statement
The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
AASLD designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE(Nurse)
The Institute for Advancement of Human Behavior is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This course is co-provided by IAHB and AASLD. Maximum of .75 contact hours.

Target Audience
This curriculum was developed for medical professionals with little or no experience providing care to patients with HCV.

Components
-Online interactive, narrated module 30 to 40 minutes in length
-Pre-and post-test questions
-Evaluation
EXPAND
COLLAPSE

Module 3: Patient Selection

CME/CE(NURSE) ACTIVITY


Michelle Baytarian
Michelle Baytarian
Disclosure(s): Nothing to disclose 
32 slide(s)– English – 2012-10-01
Extra Features Available
-Discuss three barriers to treatment of chronic hepatitis C
-Review three factors that can negatively impact a patient's response to treatment
-Demonstrate an understanding of the role of a multidisciplinary team in the treatment of a patient with chronic hepatitis C
Ho SB, Groessl E, Dollarhide A, Robinson S, Kravetz D, Dieperink E. "Management of chronic hepatitis C in veterans: the potential of integrated care models." Am J Gastroenterol. 2008 Jul;103(7):1810-23.
[See Reference]
Media: Internet
Release date: November 10, 2012
Updated Date: November 10, 2013
Expiration date: November 10, 2014
The slide set was reviewed by the author and no updates were needed.
Time to complete the activity: 45 minutes

CME
Accreditation Statement
The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
AASLD designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE(Nurse)
The Institute for Advancement of Human Behavior is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This course is co-provided by IAHB and AASLD. Maximum of .75 contact hours.

Target Audience
This curriculum was developed for medical professionals with little or no experience providing care to patients with HCV.

Components
-Online interactive, narrated module 30 to 40 minutes in length
-Pre-and post-test questions
-Evaluation
EXPAND
COLLAPSE

Module 4: Initiating HCV Treatment: The First 8 Weeks

CME/CE(NURSE) ACTIVITY


Helen S. Yee, PharmD
Helen S. Yee, PharmD
Disclosure(s): Nothing to disclose  
37 slide(s)– English – 2012-10-01
-Describe the proper use and management of hepatitis C protease inhibitors (PIs), peginterferon (PEG-IFN), and ribavirin (RBV) for the treatment of chronic HCV genotype 1 infection
-Identify monitoring and laboratory tests relevant to HCV management
-Develop strategies to minimize adverse effects related to HCV antiviral treatment
Ghany MG, Strader DB, Thomas DL, Seef LB; American Association for the Study of Liver Diseases. "Diagnosis, management, and treatment of hepatitis C: An update." Hepatology. 2009 Apr; 49(4):1335-74.
[See Reference]

Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. "An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases." Hepatology. 2011 Oct; 54(4):1433-44.
[See Reference]

Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, Monto A; Department of Veteran Affairs Hepatitis C Resource Center Program; National Hepatitis C Program Office."Update on the management and treatment of hepatitis C virus infection: Recommendations from the Department of Veteran Affairs Hepatitis C Resource Center program and the National Hepatitis C Program Office." Am J Gastroenterol. 2012 May; 107(5):669-89.
[See Reference]

Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators."Boceprevir for untreated chronic HCV genotype 1 infection." N Engl J Med. 2011 Mar 31; 364(13):1195-206.
[See Reference]

Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team."Telaprevir for previously untreated chronic hepatitis C virus infection." N Engl J Med. 2011 Jun 23; 364(25):2405-16.
[See Reference]

Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R; HCV RESPOND-2 Investigators."Boceprevir for previously treated chronic HCV genotype 1 infection." N Engl J Med. 2011 Mar 31; 364(13):1207-17.
[See Reference]

Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team."Telaprevir for retreatment of HCV infection." N Engl J Med. 2011 Jun 23; 364(25):2417-28.
[See Reference]
Media: Internet
Release date: November 10, 2012
Updated Date: November 10, 2013
Expiration date: November 10, 2014
The slide set was reviewed by the author and no updates were needed.
Time to complete the activity: 45 minutes

CME
Accreditation Statement
The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
AASLD designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE(Nurse)
The Institute for Advancement of Human Behavior is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This course is co-provided by IAHB and AASLD. Maximum of .75 contact hours.

Target Audience
This curriculum was developed for medical professionals with little or no experience providing care to patients with HCV.

Components
-Online interactive, narrated module 30 to 40 minutes in length
-Pre-and post-test questions
-Evaluation
EXPAND
COLLAPSE

Module 5: Managing Side Effects of Therapy

CME/CE(NURSE) ACTIVITY


Michele Wetmore, MSN, ANP-BC, NP-C
Michele Wetmore, MSN, ANP-BC, NP-C
Disclosure(s): Nothing to disclose  
43 slide(s)– English – 2012-10-01
-Discuss interventions for side effect management during hepatitis C treatment
McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK."Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C." N Engl J Med. 1998 Nov 19; 339(21):1485-92.
[See Reference]

Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators."Boceprevir for untreated chronic HCV genotype 1 infection." N Engl J Med. 2011 Mar 31; 364(13):1195-206.
[See Reference]

Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, Monto A; Department of Veteran Affairs Hepatitis C Resource Center Program; National Hepatitis C Program Office."Update on the management and treatment of hepatitis C virus infection: Recommendations from the Department of Veteran Affairs Hepatitis C Resource Center program and the National Hepatitis C Program Office." Am J Gastroenterol. 2012 May; 107(5):669-89.
[See Reference]
Media: Internet
Release date: November 10, 2012
Updated Date: November 10, 2013
Expiration date: November 10, 2014
The slide set was reviewed by the author and no updates were needed.
Time to complete the activity: 45 minutes

CME
Accreditation Statement
The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
AASLD designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE(Nurse)
The Institute for Advancement of Human Behavior is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This course is co-provided by IAHB and AASLD. Maximum of .75 contact hours.

Target Audience
This curriculum was developed for medical professionals with little or no experience providing care to patients with HCV.

Components
-Online interactive, narrated module 30 to 40 minutes in length
-Pre-and post-test questions
-Evaluation
EXPAND
COLLAPSE